Introduction: Monophasic Salmonella enterica strains presenting the antigenic shame 1,4,[5],12:i:- are becoming more prevalent. Accurate identification of such strains is hard with routine using biochemical and serological tests. Such strains can be identified with molecular tests. In this study we have tested the usefulness of(GTG)4-PCR for the diagnostic of such monophasic strains. This usefulness of this method was previously confirmed for genoserotyping of S. Enterica, Typhimurium, Infantis, Virchow, Hadar, Newport and Anatum.
Materials And Methods: 76 strains with antigenic shame l,4,[5],12:i:-, isolated in Poland in years 2007-12 were tested. Additionally (GTG)4-PCR patterns were obtained for reference strains of serotypes S. Lagos, S. Agama, S. Farsta, S. Tsevie, S. Glocester and S. Tumodi. (GTG)4-PCR was performed with DreamTaq DNA polymerase. Obtained patterns were analysed with BioNumerics software.
Results: No pattern specific for monophasic pattern was identified. Additionally it was also impossible to differentiate patterns obtained for S. Typhimurium, S. Farsta, S. Tsevie and S. Glocester. Only reference strains of serotypes S. Tumodi, Farsta and Agama has the distinguishable patterns of (GTG)4-PCR.
Conclusions: Analysed (GTG)4-PCR method do not show the ability to distinguish S. enterica serotypes from group 04, H:i, including monophasic strains with the antigenic shame 1,4,[5],12:i:-.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies.
Gastro Hep Adv
July 2023
Hepatitis B Foundation, Doylestown, Pennsylvania.
Chronic hepatitis B virus (HBV) infection affects about 262 million people worldwide, leading to over 820,000 deaths each year primarily due to cirrhosis and hepatocellular carcinoma. The World Health Organization has pledged to eliminate HBV as a health threat by 2030, but currently, no countries are on track to achieve this goal. One of the barriers to HBV elimination is stigma, causing shame, denial, self-isolation, self-rejection, and depression leading to those with chronic HBV less likely to get tested or seek treatment and more likely to conceal their infection.
View Article and Find Full Text PDFAnti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Nature
March 2024
Genentech Inc., South San Francisco, CA, USA.
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone. However, there remains little consensus on the mechanism(s) of response with this combination.
View Article and Find Full Text PDFCombined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Tumour Biol
March 2024
Oncology Biomarkers Development, Genentech, San Francisco, CA, USA.
Background: Patients with non-small cell lung cancer (NSCLC) and stable disease (SD) have an unmet clinical need to help guide early treatment adjustments.
Objective: To evaluate the potential of tumor biomarkers to inform on survival outcomes in NSCLC SD patients.
Methods: This post hoc analysis included 480 patients from the IMpower150 study with metastatic NSCLC, treated with chemotherapy, atezolizumab and bevacizumab combinations, who had SD at first CT scan (post-treatment initiation).
Effector-mediated subversion of proteasome activator (PA)28αβ enhances host defense against Legionella pneumophila under inflammatory and oxidative stress conditions.
PLoS Pathog
June 2023
Division of Biology, Kansas State University, Manhattan, Kansas, United States of America.
Article Synopsis
- Legionella pneumophila is a germ that can make people sick, especially those with weak immune systems, by living inside specific immune cells called macrophages.
- The germ uses special proteins to help it survive and replicate inside the cells, but some of these proteins can also boost the immune system to fight off the infection.
- One protein, called LegC4, helps the immune cells destroy the bacteria by improving how they handle stressed and damaged proteins, suggesting a new way to help the body defend against L. pneumophila.
An embarrassment of riches: RORγt antigen-presenting cells in peripheral tolerance.
Immunity
November 2022
Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address:
Article Synopsis
- RORγt regulatory T (Treg) cells play a vital role in keeping the gut's immune system balanced and tolerant.
- Recent research published in Nature by Kedmi et al., Lyu et al., and Akagbosu et al. focuses on MHCIIRORγt antigen-presenting cells that help in the differentiation of RORγt Treg cells.
- However, the studies suggest different identities for these antigen-presenting cells, leading to varied interpretations within the research community.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!